Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma.
- Author:
Yu-Nong GAO
1
;
Jing-Xian LIU
;
Wen WANG
;
Wei-Fan LI
;
Wang-Shu TANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; CA-125 Antigen; blood; Cisplatin; therapeutic use; Combined Modality Therapy; Cyclophosphamide; therapeutic use; Cystadenocarcinoma, Papillary; blood; drug therapy; pathology; surgery; Disease-Free Survival; Doxorubicin; analogs & derivatives; therapeutic use; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; blood; drug therapy; pathology; surgery; Paclitaxel; Peritoneal Neoplasms; blood; drug therapy; pathology; surgery; Retrospective Studies; Taxoids; therapeutic use
- From: Chinese Journal of Oncology 2005;27(3):171-173
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEExtraovarian peritoneal serous papillary carcinoma (EPSPC) is both histologically and clinically similar to stage III-IV ovarian papillary serous carcinoma (OPSC). The purpose of this study is to investigate the clinical findings, treatment, and outcome of EPSPC patients compared with stage III-IV OPSC patients.
METHODSThe data of 12 EPSPC patients and 45 stage III-IV OPSC patients were retrospectively reviewed, comparing the characteristics on clinical presentation and treatment, sensitivity to first-line chemotherapy agents and survival.
RESULTSBy analysis of patients' characteristics, presenting signs and symptoms, type and extent of surgery, tumor response to first-line chemotherapy, recurrence-free interval, recurrence site and serum CA-125 levels, no significant difference was observed between the EPSPC patients and stage III-IV OPSC controls. The prevailing presenting symptoms were abdominal mass and ascites. The mainstay of treatment was debulking surgery followed by adjuvant platinum-based chemotherapy. The complete clinical response of stage III-IV OPSC was 91.8% compared with 25.0% for women with EPSPC (P < 0.01).
CONCLUSIONThe clinical and surgical characteristics of EPSPC are similar to those of stage III-IV OPSC. When the same treatment strategy is applied, similar response and survival are expected in either condition.
